Cohance Lifesciences Resubmits Q2 FY26 Unaudited Financial Results
Cohance Lifesciences Limited re-submitted its Q2 FY26 unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025, with no changes from the November 12, 2025 submission. Standalone revenue was ₹497.79 crore and net profit ₹94.19 crore. Consolidated revenue was ₹555.57 crore and net profit ₹66.39 crore.
The announcement is a procedural re-submission of already disclosed financial results, therefore it has a low impact on the company's stock.
The announcement is a re-submission of previously filed financial results with no changes, hence it is neutral.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has re-submitted its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. These results, prepared under Ind AS, were originally submitted on November 12, 2025, and the re-submission on December 15, 2025, confirms there are no changes to the previously declared financial figures.
The company's Board of Directors had approved these financial results at a meeting held on November 12, 2025. The financial statements include the revenue from operations, expenses, profit before tax, net profit, and other comprehensive income for both standalone and consolidated entities. The results also detail the company's assets and liabilities as of September 30, 2025, and provide cash flow statements for the half-year ended September 30, 2025.
Key financial highlights for the quarter ended September 30, 2025, include standalone revenue from operations of ₹497.79 crore and a net profit of ₹94.19 crore. On a consolidated basis, revenue from operations stood at ₹555.57 crore with a net profit of ₹66.39 crore attributable to shareholders. The company also provided earnings per share (EPS) figures for both standalone (₹2.46 basic, ₹2.46 diluted) and consolidated (₹1.94 basic, ₹1.93 diluted) results.
Significant notes accompanying the results detail the amalgamation of Casper Pharma Private Limited and the erstwhile fellow subsidiary, Cohance Lifesciences Limited (now the holding company), with the current entity. The company also reported the acquisition of 56% of the share capital of NJ Bio Inc on December 20, 2024, for a consideration of ₹547.96 crore, which has been included in the consolidated financial results from that date.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.